LifeMD, Inc. (NASDAQ:LFMD) Given Average Rating of “Moderate Buy” by Analysts

LifeMD, Inc. (NASDAQ:LFMD) has been assigned an average rating of “Moderate Buy” from the ten brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $9.1429.

Several analysts have recently commented on LFMD shares. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of LifeMD in a research report on Tuesday, May 26th. UBS Group restated a “buy” rating on shares of LifeMD in a research report on Wednesday, May 27th. BTIG Research reaffirmed a “buy” rating and issued a $10.00 target price on shares of LifeMD in a research note on Monday, May 4th. Wall Street Zen cut LifeMD from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings raised LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a research report on Thursday, May 7th.

LifeMD Price Performance

LifeMD stock opened at $4.15 on Monday. LifeMD has a 52 week low of $2.56 and a 52 week high of $12.72. The firm’s 50-day simple moving average is $4.55 and its 200 day simple moving average is $3.97. The firm has a market capitalization of $200.69 million, a PE ratio of 83.02 and a beta of 1.99.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.06). The business had revenue of $50.16 million during the quarter, compared to analyst estimates of $48.84 million. LifeMD had a net margin of 2.37% and a negative return on equity of 150.88%. On average, research analysts expect that LifeMD will post -0.37 EPS for the current fiscal year.

Institutional Trading of LifeMD

A number of large investors have recently made changes to their positions in the stock. Bank of America Corp DE increased its position in LifeMD by 10.1% during the 1st quarter. Bank of America Corp DE now owns 48,703 shares of the company’s stock worth $176,000 after purchasing an additional 4,465 shares in the last quarter. Sei Investments Co. acquired a new position in LifeMD in the 1st quarter valued at about $148,000. State of Wyoming lifted its holdings in LifeMD by 146.9% in the 1st quarter. State of Wyoming now owns 142,499 shares of the company’s stock valued at $514,000 after purchasing an additional 84,785 shares in the last quarter. R Squared Ltd purchased a new position in LifeMD in the 1st quarter valued at about $41,000. Finally, Aristides Capital LLC acquired a new stake in shares of LifeMD during the 4th quarter worth about $203,000. Institutional investors and hedge funds own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.